- Home
- BIIB vs FCNCA Comparison
BIIB vs FCNCA Comparison
Compare BIIB & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FCNCA
- Stock Information
- Founded
- BIIB 1978
- FCNCA 1898
- Country
- BIIB United States
- FCNCA United States
- Employees
- BIIB N/A
- FCNCA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FCNCA Major Banks
- Sector
- BIIB Health Care
- FCNCA Finance
- Exchange
- BIIB Nasdaq
- FCNCA Nasdaq
- Market Cap
- BIIB 18.8B
- FCNCA 25.4B
- IPO Year
- BIIB 1991
- FCNCA N/A
- Fundamental
- Price
- BIIB $132.82
- FCNCA $2,088.73
- Analyst Decision
- BIIB Buy
- FCNCA Buy
- Analyst Count
- BIIB 27
- FCNCA 10
- Target Price
- BIIB $188.17
- FCNCA $2,348.40
- AVG Volume (30 Days)
- BIIB 1.3M
- FCNCA 83.6K
- Earning Date
- BIIB 07-31-2025
- FCNCA 07-25-2025
- Dividend Yield
- BIIB N/A
- FCNCA 0.37%
- EPS Growth
- BIIB 26.39
- FCNCA N/A
- EPS
- BIIB 10.12
- FCNCA 175.01
- Revenue
- BIIB $9,816,400,000.00
- FCNCA $9,091,000,000.00
- Revenue This Year
- BIIB N/A
- FCNCA N/A
- Revenue Next Year
- BIIB N/A
- FCNCA $2.54
- P/E Ratio
- BIIB $13.13
- FCNCA $11.94
- Revenue Growth
- BIIB 1.59
- FCNCA N/A
- 52 Week Low
- BIIB $110.04
- FCNCA $1,473.62
- 52 Week High
- BIIB $238.00
- FCNCA $2,412.93
- Technical
- Relative Strength Index (RSI)
- BIIB 59.57
- FCNCA 76.83
- Support Level
- BIIB $123.90
- FCNCA $1,952.21
- Resistance Level
- BIIB $134.75
- FCNCA $1,946.00
- Average True Range (ATR)
- BIIB 3.50
- FCNCA 41.88
- MACD
- BIIB 0.28
- FCNCA 23.67
- Stochastic Oscillator
- BIIB 83.71
- FCNCA 92.00
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FCNCA First Citizens BancShares Inc.
First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through our extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.